The company revealed in a press release that it has completed accrual accounting (i.e., it has finalized data collection) for the first interim analysis of the Phase 3 trial of mRNA-1273. Moderna’s candidate is one of the few to have reached an advanced stage of testing. He added that he is preparing the data for submission to the Independent Data and Safety Oversight Council of the National Institutes of Health (NIH) for further review and recommendation.
Moderna expects to be able to announce the results by the end of this month.
Last month, Moderna completed recruiting 30,000 participants in the US study, in which half of the participants were given mRNA-1273 and the other half were given a saline placebo.
The company is participating in the federally sponsored Operation Warp Speed initiative, which aims to rapidly develop and distribute COVID-19 treatments and vaccines. The advanced mRNA-1273 assay was designed in coordination with the NIH and the Food and Drug Administration (FDA).
Moderna’s announcement comes amid a surge in COVID-19 cases and deaths in the U.S. It also comes days after another vaccine candidate, BNT162b2 from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), has demonstrated extremely high efficacy in its advanced stage tests.
Investors will be following Moderna, Pfizer and BioNTech closely to assess which company (or companies) will eventually get ahead of the coronavirus vaccine race.
Moderna’s share rose 1.8% on Friday, eclipsing the gains of the S&P 500 index of the day.